Farma
Haltopen
04.10.2021 kl 08:44
3177
DnB Markets:
Data point indicates larger than expected cardiac market
We expect Gentian Diagnostics to have seen business as usual in Q3 and forecast organic sales growth of 48%
YOY. The cash position remains solid, with pipeline projects progressing in accordance with timelines, we
believe. A recent new data point indicates a c3x larger market opportunity for cardiac marker NT-proBNP than
we previously expected, mainly due to higher testing volumes in the US. We have updated our testing volume
assumptions and lowered our peak uptake estimate. As a result, we have increased our target price to NOK104
(84), and reiterate our BUY.
Data point indicates larger than expected cardiac market
We expect Gentian Diagnostics to have seen business as usual in Q3 and forecast organic sales growth of 48%
YOY. The cash position remains solid, with pipeline projects progressing in accordance with timelines, we
believe. A recent new data point indicates a c3x larger market opportunity for cardiac marker NT-proBNP than
we previously expected, mainly due to higher testing volumes in the US. We have updated our testing volume
assumptions and lowered our peak uptake estimate. As a result, we have increased our target price to NOK104
(84), and reiterate our BUY.
Redigert 04.10.2021 kl 08:44
Rapportér innlegg
Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.